The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatments-induced cardiac toxicity in a global approach. Many factors should be considered...
Le trastuzumab (Herceptin ® ), un anticorps monoclonal humanisé anti-HER2 (human epidermal growth factor receptor), est le premier traitement ciblant un facteur de croissance (et de différenciation) membranaire de la famille des Her 1 à 4. Vingt ans après sa découverte, cet anticorps aura bouleversé le pronostic dans une population de patientes atteinte d'une forme de cancer du sein parmi...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.